1 / 35

Douglas S. Hawkins, Kristy Seidel, Mark Krailo, Leo Mascarenhas, Paul Meyers, Neyssa Marina, Ernest U. Conrad Connectiv

Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children’s Oncology Group. Douglas S. Hawkins, Kristy Seidel, Mark Krailo, Leo Mascarenhas, Paul Meyers, Neyssa Marina, Ernest U. Conrad

maura
Download Presentation

Douglas S. Hawkins, Kristy Seidel, Mark Krailo, Leo Mascarenhas, Paul Meyers, Neyssa Marina, Ernest U. Conrad Connectiv

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children’s Oncology Group Douglas S. Hawkins, Kristy Seidel, Mark Krailo, Leo Mascarenhas, Paul Meyers, Neyssa Marina, Ernest U. Conrad Connective Tissue Oncology Society November 2008

  2. Results • 498 patients in INT-0133 OS CT trial • BMI breakdown: • Low BMI (<10%): 73 patients (14.7%) • Middle BMI (10-94%): 382 patients (76.7%) • High BMI (>95%): 43 patients (8.6%) • Complications: • Any: 76 patients (15.3%) • Wound slough: 52 patients (10.5%) • Infection: 15 patients (3.0%) • Hematoma: 15 patients (3.0%) • Thrombosis: 6 patients (1.2%) • Hemorrhage: 4 patients (0.8%) Bert Uwe Drechsel

  3. Results • Wound slough or infection: • Low BMI: 14 patients (19.2%) OR=2.0 (p=0.04) • Middle BMI: 40 patients (10.5%) Reference • High BMI: 7 patients (16.3%) OR =1.7 (p=0.25) • Thrombosis: • Low BMI: 0 patients (0%) OR=1.4 (p=1.0) • Middle BMI: 3 patients (0.8) Reference • High BMI: 3 patients (7.0%) OR=9.4 (p=0.03) Bert Uwe Drechsel

  4. Conclusions: • Low BMI at study entry for patients with localized osteosarcoma receiving neo-adjuvant chemotherapy is associated with an increased risk of wound infection or wound slough after delayed definitive surgery • Future studies should evaluate whether correction of malnutrition reduces the risk of surgical complication Bert Uwe Drechsel

  5. Qqqqqq • This study measured BMI at start of Rx – did you look at change in BMI as a more potent cause of problems – eg the underweight child who loses weight? • Were wound problems related to toxicity of chemotherapy? Bert Uwe Drechsel

  6. The Presence of Pleural Effusion in Sarcomatous Pulmonary Metastatic Disease Does Not Affect Survival Simon Jordan,  Peter Goldstraw,  Elizabeth Belcher,  Ambrus Szántho,  Jeremy Whelan*,  Beatrice Seddon*,  Maria Michelagnoli*, Anna Cassoni*,  Sandra Strauss*,  Michelle Scurr+,  Frank Saran+, Ian Judson+,  George Ladas Royal Brompton Hospital, London, United Kingdom; *University College Hospital, London, United Kingdom; +Royal Marsden Hospital, London, United Kingdom

  7. Objectives and Methods Prolonged survival following pulmonary metastasectomy is well documented. However, the presence of a pleural effusion raises concerns as to the suitability of aggressive treatment. The prognostic significance of such effusions has not been addressed. Retrospective assessment of 105 consecutive patients operated on by a single surgeon undergoing pulmonary metastasectomy for sarcomatous disease between 01/01/95 and 31/03/2007 was undertaken. Kaplan-Meier methods, Log-rank test and Cox regression models were utilised to compare survival.

  8. Results and Conclusions 105 patients underwent 157 metastasectomy procedures. Operative mortality was 0%. Operative mortality was 51.7% at 5 years and 46.7% at 10 years. A pleural effusion was present pre-operatively in 11 of 105 patients. In 7 patients the effusion was haemorrhagic. The presence of a pleural effusion, did not affect prognosis (HR 1.44 (CI: 0.61-3.4, p=0.408)). Moreover, a haemorrhagic pleural effusion did not influence survival (HR 1.49 (CI: 0.53-4.17, p=0.447)). We suggest that the presence of a pleural effusion should not preclude patients from undergoing pulmonary metastasectomy. Patients at risk 105 57 34 27 1611 10 6 4 2 Figure. 1. Overall survival following lung metastasectomy in sarcoma patients.

  9. Qqqqq • Was surgical technique any different for patients with a pleural effusion? • Did the surgeon find pleural metastases more commonly in these cases? • If a pleural metastasis was found ‘stuck’ to the chest wall – was the chest wall resected ‘en bloc’?

  10. Survey: Mangement of Pulmonary Metastatic OsteosarcomaD. Carrle, S. Bielack – COSS Stuttgart Background: Evidence: Detection: No perfect imaging method Treatment: Complete surgical resection of all malignant leseions in osteosarcoma Lack of evidence: Practical diagnostic and therapeutic aspects of management. Purpose: Survey to determine current practice of experts in the field. Method: Postal survey addressing 17 representatives from international study groups and selected institutions. Results: Response rate: 94%

  11. Conclusion: • Survey amongst experts in the field: • generates new (1, 6) or substantiate (3, 4, 7) existing evidence ( Level 5, °D) • exposes controversies in some areas (5, 8, 9). • Prospective studies needed - Join SAREZ/TranSaRNet Consortium • (Sarcoma Registry)!

  12. Qqqqq • Unilateral disease – bilateral exploration - what is hit rate for finding abnormalities • Role of better imaging for the 5mm nodules? ? PET • What happens to cases of disappearing mets?

  13. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group AJ Chou, ES Kleinerman, MD Krailo, Z Chen, DL Betcher, JH Healey, EU Conrad, H Nadel, ML Nieder, J Sato, MA Weiner, RJ Wells, RB Womer, PA Meyers, on behalf of the Children’s Oncology Group • 21 patients with OS + mets at diagnosis • Randomized to chemo • A - Ad/Cisplat/HDMTX + MTPE • B - Ad/Cisplat/HDMTX/Ifos + MTPE

  14. Results: Overall Survival

  15. Conclusions Predictors of poor outcome Race (Hispanic worse) Gender (males worse) Non-pulmonary sites of disease High alkaline phosphatase, LDH Number of pulmonary nodules did not appear to predict poor outcome  ? Significance ? Explanation The pattern seen in the metastatic cohort was similar to the non-metastatic cohort with the same reduction in the relative risk of death associated with the addition of L-MTP-PE to conventional chemotherapy, but the improvement did not reach conventional levels of statistical significance

  16. Qqqqqqq • Did surgical operability effect prognosis • Future role of MTPE ?

  17. Sentinel node biopsy in soft tissue sarcoma of the extremities. A single-center experience Dimosthenis Andreou S. Fehlberg, C. Tiedke, S. Richter, D. Pink, P.-U. Tunn Dimosthenis Andreou

  18. Sentinel node biopsy in soft tissue sarcoma of the extremities - Results • a series of 22 consecutive patients with synovial sarcoma (n=17), clear cell sarcoma (n=2), epithelioid sarcoma (n=2) and rhabdomyosarcoma (n=1) underwent a sentinel node biopsy • 2 positive, 1 false negative and 24 negative sentinel nodes were identified • at least one sentinel was detected in each patient • no biopsy-related complications were observed Dimosthenis Andreou

  19. Sentinel node biopsy in soft tissue sarcoma of the extremities - Discussion • up to date there is no validated, non-invasive method to assess regional lymph node status in patients with soft tissue sarcoma • SN-biopsy can be successfully and safely applied • further prospective studies are required to determine the clinical relevance and the prognostic significance of SN-biopsy in soft tissue sarcoma Dimosthenis Andreou

  20. Qqqqqq… • Which were the +ve cases? • Was there any clinical or radiological suspicion in those? • Did it alter management? • Is it cost effective? Dimosthenis Andreou

  21. Surgery of giant cell tumor of the sacrum: an analysis of 28 cases Ruggieri P., Ussia G., Bosco G., Angelini A., Montalti M., Pala E., Biagini R., Mercuri M. Department of Orthopedics, University of Bologna, Istituto Ortopedico Rizzoli

  22. Material and methods • 28 cases (1986-2006) • • retrospective study • • age range: 4 – 68 ys. (mean age 30) • • mean follow-up 9.6 ys. ( min.2- max.22 ) • No lung metastases at dx., no multicentric GCTs • Neurologic deficits at presentation 43% • Stage 3 GCT 89% • Previous treatment elsewhere in 4 cases • S 1 was involved in 82% of the cases (23/28)

  23. Surgical treatment: intralesional excision in 28 cases • Surgical approach: - Anterior and posterior 14 cases - Posterior 13 cases - Anterior 1 cases (death after 14 day of surgery) • Radiotherapy (adjuvant) in 20 cases, average dose 43.5 Gy (min.36- max.70 Gy) • Preoperative selective arterial embolization in 22 cases: - 2 times in 2 cases - 1 time in 20 cases • Local adjuvants in 17 cases: phenol (16), liquid nitrogen (3) - 14 cases phenol - 1 case liquid nitrogen - 2 cases both

  24. Treatment and results • 24 cases NED • Local Recurrence in 3 cases ( 2 NED1, 1 DOD with radio-induced sarcoma) • 1 DOD with postoperative massive pulmonary embolism • Overall mortality 7.1% (2/28) • Perioperative mortality 3.6% (1/28) • Overall LR rate 11% (3/27): • - 1 LR/7 cases with surgery only (14%) • - 2 LR/20 cases with surgery and radiotherapy (10%) • Radio-induced sarcoma 5% (1/20) • No lung metastases • Postoperative neurologic deficit 48% • CONCLUSIONS: recommended treatment is surgical excision with local adjuvants, without radiotherapy • pietro.ruggieri@ior.it

  25. Some reports suggest embolisation itself may cure many of these patients….. How control bleeding if no embolisaton? What is follow up for RT treated patients? How many neurologically worse after surgery than before? Do you foresee any role for biphosphonates / denosumab in these cases? Qqqqqq

  26. THE CLINICAL AND FUNCTIONAL OUTCOME FOR RADIATION-INDUCED SOFT-TISSUE SARCOMA IN ADULTS • Purpose: • To compare the clinical and functional outcome of patients with radiation-induced soft tissue sarcomas (RI-STS) to those with primary extremity soft-tissue sarcoma. • Methods: • Retrospective data from 4 centers were collected for RI-STS cases treated from 1989-2004. • 33 patients with median age of 54.5 years • Median period from irradiation of primary cancer to RI-STS was18 years (3-56 years). • 4/31 patients had positive resection margins. • 42% of RI-STS developed a systemic relapse and 24% developed a local recurrences Soha Riad, Anthony Griffin, Ginger Holt, Cindy Wong, Joel Werier, Robert Turcotte, Peter Ferguson, Benjamin Deheshi, Brian O’Sullivan, Jay Wunder Musculoskeletal Oncology Unit, Mount Sinai, Vanderbilt Medical Center, McGill University Health Center, Ottawa Hospital-General Campus, Departments of Radiation Oncology and Surgical Oncology, Princess Margaret Hospital, University Health Network, The University of Toronto

  27. RI-STS 5-year overall survival was 39% compared to 72% for the Other STS group. • 14 patients had postoperative functional assessment using TESS and MSTS1987 scores; mean 83 (61-100), 27 (17-33) respectively, compared to 86 (13-100), 30 (14-35) for the Other STS population. Conclusions • Patients with RI-STS have a poor prognosis due to high local and systemic recurrence rates. • Limb salvage and negative margins were obtainable for most of the RI-STS group. • Good functional results are possible for these patients. • Novel systemic treatments are necessary to help improve their oncologic outcomes. Other STS Group RI-STS Group p = 0.0002 p = > 0.00001

  28. Qqqqqqq • What most the common site • What was the most common primary • In how many did you feel there may be a ‘field change’ rather than a single focus • Could you use further RT in any? • Chemotherapy?

  29. The Functional Consequence of Femoral Nerve Resection in the ThighKevin B. Jones*†, Soha Riad*, Anthony M. Griffin*, Benjamin Deheshi*, Robert S. Bell*, Peter C. Ferguson*, Jay S. Wunder**University Musculoskeletal Oncology Unit, Mount Sinai and Princess Margaret Hospitals, University of Toronto. †Sarcoma Services, Huntsman Cancer Institute and the Department of Orthopaedic Surgery, University of Utah. Findings • 10 patients retrospectively identified from a prospective sarcoma database had undergone complete femoral nerve ablation during soft tissue sarcoma resection. • Compared to sciatic nerve resection patients, a non-nerve-involved thigh sarcoma control group, and a gender-matched control group, TESS, MSTS1987, and MSTS1993 trended toward worse outcomes among the 10 patients with femoral nerve resection. Statistical significance was not reached. • 6 of the 10 patients suffered a total of 8 fractures following complete femoral nerve resection, many in the contralateral limb, due to frequent falls.

  30. The Functional Consequence of Femoral Nerve Resection in the ThighKevin B. Jones*†, Soha Riad*, Anthony M. Griffin*, Benjamin Deheshi*, Robert S. Bell*, Peter C. Ferguson*, Jay S. Wunder**University Musculoskeletal Oncology Unit, Mount Sinai and Princess Margaret Hospitals, University of Toronto. †Sarcoma Services, Huntsman Cancer Institute and the Department of Orthopaedic Surgery, University of Utah. Relevance • Sciatic nerve resection in the thigh changed from a categorical indication for amputation to an undertaking compatible with limb salvage when functional outcomes were carefully studied. • In contrast, it appears that the functional morbidity of femoral nerve resection may have been under-estimated in the absence of nerve-specific outcomes data, perhaps because complete extensor power ablation is somewhat commonly associated with distal femur resection and reconstruction in the sarcoma world, but the effects are there mitigated by implant hyperextension. • Functional outcomes, as well as fall-preventive interventions, following femoral nerve resection for soft tissue sarcoma merit further attention and study, as do other nerve-specific functional outcomes.

  31. Qqqqqqq • Did any of the patients have a brace? • Did any have a tendon graft? • Anyone know a good reconstruction following excision of the femoral nerve?

  32. Injectionofmetilprednisoloneacetate in the treatment ofeosinophilic granuloma ofbone. G. Bosco, A. Bosco, G. Paone, E. Pala,T. Calabrò, P. Ruggieri DepartmentofOrthopedics, Universityof Bologna, Istituto Ortopedico Rizzoli

  33. Injectionofmetilprednisolone acetato in treatment of the eosinophilic granuloma ofbone 50 cases (Jan 1994 - Dec 2004) 31 - 19 Age: 9.7 yrs (min 2 – max 60) Site: Lowerlimb 17 Upper Limb 12 Pelvis 11 Spine 4 Multiple localizations 6* Follow up: 36.7 months (min 3 - max 94) *all pts. received systemic therapy (Vinblastin+Prednisone) 2 had previous Prednisone local injection

  34. Injectionofmetilprednisolone acetato in treatment of the eosinophilic granuloma ofbone 40 pts. healedwith a single injection meantimetoradiografichealing-> 9 months • Conclusions • steroidsinjectioneffective in single bonelesions • no furtherinjectionsif at 3 mos. positive X rayschanges • multiple lesionsrequiresystemic treatment One Months Five Months At the Beginning Ten Months Three Months

  35. How many Eosinophilic granulomas Rx in the same time period without steroid injection? How many healed without injection? What are indications for steroid injection? Qqqqqq

More Related